# What to ask before agreeing to joint care *Joint Regeneration Glendale | What to Ask About the Label* > For people comparing stem cell therapy for joints, this joint regeneration Glendale page gives plain questions about what goes into the shot. Pulling on a shirt can expose shoulder soreness before the day gets moving. Knee soreness may first appear on stairs or when standing after a meal. A treatment name can't show what caused either ache or which care may fit. A doctor checks motion, strength and old injuries, then explains which chores seem safe now. During the exam, say when a movement starts hurting and when it feels weak. Those answers help the doctor set safer limits for chores at home. ## What to ask about what's in the shot Ask whether the shot contains part of your blood, marrow, fat or donated tissue. Then ask where the shot goes and who will prepare it. Blood comes from a blood draw, while marrow or fat must be collected another way. Don't accept a claim about repair as proof that worn joint tissue will grow back. ## What to ask about the likely result Less aching and easier motion don't mean an X-ray will look different. Ask whether the clinic expects to watch soreness, movement or a change on a scan. No one can say exactly how one joint will respond before care begins. The answer can still cover likely limits, other choices and reasons to return early. ## What to settle before the visit ends Get the full cost, return-visit schedule and recovery limits before making a choice. Ask whether a doctor or another licensed provider gives the shot and what training that person has. At home, note changes in sleep, walking and the motion that causes soreness. QC Kinetix offers regenerative treatment choices, meaning non-surgical shots made from a person's blood and intended to support repair after its medical team reviews the joint. ## Sources 1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to. Caplan AI, et al. — [Mesenchymal Stem Cells: Time to Change the Name!](https://pubmed.ncbi.nlm.nih.gov/28452204/). *Stem cells translational medicine*, 2017. DOI: 10.1002/sctm.17-0051. 2. A Nature comment by Sipp, Robey and Turner arguing that loose use of 'mesenchymal stem cell' across an enormous range of unrelated cell preparations has produced a scientific and commercial mess, and calling for the terminology and the evidentiary standards to be tightened. Included because the objection to the word comes from inside stem cell science, not from its critics. Sipp D, et al. — [Clear up this stem-cell mess.](https://pubmed.ncbi.nlm.nih.gov/30258150/). *Nature*, 2018. DOI: 10.1038/d41586-018-06756-9. 3. The study that first mapped the scale of the US direct-to-consumer stem cell industry, finding widespread internet marketing of unapproved stem cell interventions by businesses based in the UNITED STATES - previously assumed to be a phenomenon of countries with lax medical regulation - and concluding that regulators must better oversee this marketplace. Turner L, et al. — [Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.](https://pubmed.ncbi.nlm.nih.gov/27374789/). *Cell stem cell*, 2016. DOI: 10.1016/j.stem.2016.06.007. 4. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX at Level III evidence or higher (4 Level II, 2 Level III), covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment - meaning no consensus exists on indications, cell sources, preparation or delivery. Two products called 'stem cell therapy' at two clinics may share almost nothing. Chahla J, et al. — [Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.](https://pubmed.ncbi.nlm.nih.gov/27655978/). *The Journal of bone and joint surgery. American volume*, 2016. DOI: 10.2106/JBJS.15.01495. 5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA*, 2020. 6. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 7. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 8. Medicare's National Coverage Determination covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure or venous WOUNDS, and only under Coverage with Evidence Development inside an approved clinical research study. There is no Medicare coverage pathway for PRP as a treatment for osteoarthritis or any other joint indication, which is why these injections are quoted as cash prices. Centers for Medicare & Medicaid Services — [Autologous Platelet-rich Plasma (Coverage with Evidence Development)](https://www.cms.gov/medicare/coverage/evidence/plasma). *CMS.gov*, 2012. ## What to bring to the clinic Bring notes on the soreness, a medicine list and records from earlier care. QC Kinetix can review those details and discuss a non-surgical shot prepared from a person's own blood. The Peoria office may suit north Glendale, while Banner Estrella may be simpler from the south side. Call (602) 837-PAIN to ask about scheduling. Talk to the clinic team: --- Clear answers for a sore joint. Joint regeneration Glendale information on common soreness, home care, warning signs, visits and non-surgical choices near home. Plain information about aching joints, useful home steps, clinic exams and non-surgical choices near Glendale. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria and Banner Estrella locations referenced here, and the business benefits when readers book a consultation. Copyright 2026 Glendale Joint Field Guide. General education only; it does not replace an examination or individualized medical advice.